Similarly, blood cancers had a 24.5 percent response rate compared to 13.5 percent. (sciencedaily.com)
In the Phase II clinical trial, Dr. Miller and colleagues in the National Cancer Institute - supported Gynecologic Oncology Group found that in patients who had not received prior chemotherapy, the combination cocktail had a 31 percent response rate for up to 7 months, and an overall survival of 12 months. (sciencedaily.com)